Sandbox/m02
< Sandbox
| 123 | Migraine Prophylactics | Dosage | Potential Side-Effects |
| Level A Medications with established efficacy (>2 Class I trials) |
Antiepileptic drugs | ||
| ▸ Divalproex sodium | 400–600 mg twice daily | Drowsiness, weight gain, tremor, hair loss, fetal abnormalities, hematological or liver abnormalities | |
| ▸ Sodium valproate | 400–600 mg twice daily | ||
| ▸ Divalproex sodium | 250 mg twice daily | Drowsiness, weight gain, tremor, hair loss, fetal abnormalities, hematological or liver abnormalities | |
| ▸ Tobramycin | 5—20 mg | ||
| ▸ Amikacin | 5—50 mg | ||
| ▸ Polymyxin B | 5 mg | ||
| ▸ Colistin | 10 mg | ||
| ▸ Quinupristin/Dalfopristin | 2—5 mg | ||
| ▸ Teicoplanin | 5—40 mg | ||
| ▸ Amphotericin B | 0.1—0.5 mg/day | ||
References
- ↑ Silberstein, SD.; Holland, S.; Freitag, F.; Dodick, DW.; Argoff, C.; Ashman, E. (2012). "Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society". Neurology. 78 (17): 1337–45. doi:10.1212/WNL.0b013e3182535d20. PMID 22529202. Unknown parameter
|month=ignored (help) - ↑ Goadsby, PJ.; Sprenger, T. (2010). "Current practice and future directions in the prevention and acute management of migraine". Lancet Neurol. 9 (3): 285–98. doi:10.1016/S1474-4422(10)70005-3. PMID 20170842. Unknown parameter
|month=ignored (help)